Cervical Cancer Drugs Global Market Report 2024

The cervical cancer drugs market size has grown steadily in recent years. It will grow from $24.25 billion in 2023 to $25.42 billion in 2024 at a compound annual growth rate (CAGR) of 4.8%. The growth observed in the historical period can be attributed to the introduction of HPV vaccines, the development of chemotherapy agents, advancements in radiation therapy, early adoption of targeted therapies, and diagnostic advancements.

The cervical cancer drugs market size is expected to see steady growth in the next few years. It will grow to $30.77 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. The anticipated growth in the forecast period can be attributed to growing advancements in immunotherapy, the expansion of precision medicine, continued development of targeted therapies, expanded HPV vaccination programs, and innovative combination therapies. Major trends expected in the forecast period include healthcare infrastructure development, advancements in immunotherapy, the adoption of precision medicine approaches, ongoing development of targeted therapies, and the expansion of HPV vaccination programs.

The growth of the cervical cancer drugs market is being fueled by the increasing prevalence of HIV (Human Immunodeficiency Virus) in women. Women who are HIV-positive face a higher risk of cervical cancer compared to the general population. Globally, approximately 18 million women have tested positive for HIV. The weakened immune system associated with HIV increases the such as lihood of cervical cancer, with the decline in the protein CD4 count contributing to a higher diagnosis rate. According to a survey by the National Cancer Institute, individuals with HIV are three times more such as ly to be diagnosed, further driving the expansion of the cervical cancer drugs market.

The cervical cancer drug market is expected to receive a boost from the growing funding for cancer research. Cancer research involves scientific studies aimed at understanding cancer's origins, progression, and treatment. Cervical cancer drugs play a crucial role in advancing cancer research by offering insights into cancer progression mechanisms, identifying therapeutic targets, and improving disease treatment and management. In August 2023, the National Cancer Institute reported a total budget of $6.4 billion for cancer research in 2021, representing a 1.6% growth of $99.3 million compared to 2020. Consequently, the increased funding for cancer research is propelling the cervical cancer drug market.

The lack of awareness and misconceptions about cervical cancer pose challenges to the growth of the cervical cancer drugs market. Late diagnosis and subsequent deaths among women are often attributed to insufficient awareness of the disease. This lack of awareness leads to the avoidance of the disease, resulting in delayed diagnosis and treatment. A study conducted at the Bowen University Teaching Hospital in Nigeria revealed that only 22.6% of women were aware of cervical cancer, with 17.9% aware of screening tests. Health talks and hospital staff were identified as the primary sources of information.

Several significant trends are shaping the cervical cancer drugs market, facilitating efficient and targeted treatment of the disease. Advances in drug delivery, such as the use of drugs delivered directly from the vagina through formulations such as gels, creams, pessaries, rings, films, and tablets, are gaining prominence. These drugs enable localized treatment of cervical cancer, with formulations designed for easy absorption into vaginal tissue and reaching the site of action. For example, Cidofovir gel and 851B Gel have been introduced to the market, with 851B Gel currently in the trial phase. Additionally, drugs such as ISA101, AGEN2034, and Z-100 are in the pipeline, promising further growth in the cervical cancer drugs market.

Major companies operating in the cervical cancer drugs market are obtaining approvals for drugs combining chemotherapy, such as KEYTRUDA (pembrolizumab) Plus Chemotherapy. This combination aims to address PD-L1 expression in cervical cancer tumors, leading to increased revenue in the market. Merck, a US-based healthcare company, received FDA approval for KEYTRUDA in October 2021, based on successful results from the Phase 3 KEYNOTE-826 trial. The trial demonstrated that KEYTRUDA, when combined with chemotherapy, significantly improved overall and progression-free survival in patients with persistent, recurrent, or metastatic cervical cancer expressing PD-L1.

In August 2022, UK-based pharmaceutical company GSK acquired Affinivax Inc., a US-based biopharmaceutical company specializing in various drug deliveries, including cervical cancer drugs. Through this acquisition, GSK aims to expand its drug development portfolio using diverse technologies.

Major companies operating in the cervical cancer drugs market report are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Siemens Healthineers AG, Allergan PLC, Teva Pharmaceutical Industries Ltd., Mylan NV, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, Genentech Inc., QIAGEN NV, Seagen Inc., Alnylam Pharmaceuticals Inc., Akeso Biopharma Co. Ltd., Biocad Corp., Betta Pharmaceuticals Co. Ltd., Biocon Limited, ADC Therapeutics SA, Clovis Oncology Inc., Agenus Inc., Iovance Biotherapeutics Inc., MacroGenics Inc., Orano Med SA, MobileODT Inc., Sense Biodetection. North America was the largest region in the cervical cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the global cervical cancer drugs market share during the forecast period. The regions covered in the cervical cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The main types of cancer in cervical cancer drugs are squamous cell cancer and adenocarcinoma. Squamous cell carcinoma (SCC) is a type of skin cancer that originates in the squamous cells. The epidermis, the outermost layer of the skin, is composed of thin, flat cells called squamous cells. Different types of drugs used for cervical cancer treatment include Avastin, Bevacizumab, Blemocin, Blenoxane, and others. These drugs are distributed through various channels, including hospital pharmacies, retail pharmacies, and others.

The cervical cancer drugs market research report is one of a series of new reports that provides cervical cancer drugs market statistics, including cervical cancer drugs industry global market size, regional shares, competitors with a cervical cancer drugs market share, detailed cervical cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the cervical cancer drugs industry. This cervical cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The countries covered in the cervical cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cervical cancer drugs market consists of sales of Alymsys (Bevacizumab), Bevacizumab, and Bleomycin Sulfate. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.